Ambalal Sarabhai (AMBALALSA) | Financial Analysis & Statements
Ambalal Sarabhai Enterprises Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
520.0M
Gross Profit
218.3M
41.99%
Operating Income
31.2M
5.99%
Net Income
36.4M
7.00%
EPS (Diluted)
₹0.40
Balance Sheet Metrics
Total Assets
2.6B
Total Liabilities
1.1B
Shareholders Equity
1.5B
Debt to Equity
0.76
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Ambalal Sarabhai Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.0B | 1.7B | 1.7B | 1.9B | 1.6B |
| Cost of Goods Sold | 1.2B | 1.1B | 1.1B | 1.2B | 1.0B |
| Gross Profit | 723.7M | 641.9M | 622.1M | 757.9M | 589.4M |
| Gross Margin % | 37.1% | 37.1% | 36.7% | 38.9% | 36.3% |
| Operating Expenses | |||||
| Research & Development | 165.0K | 2.2M | 1.1M | 756.0K | 1.5M |
| Selling, General & Administrative | 127.3M | 126.3M | 113.3M | 124.6M | 146.5M |
| Other Operating Expenses | 162.8M | 150.8M | 157.1M | 127.6M | 70.2M |
| Total Operating Expenses | 290.3M | 279.3M | 271.5M | 253.0M | 218.1M |
| Operating Income | 92.4M | 52.4M | 70.6M | 237.7M | 59.3M |
| Operating Margin % | 4.7% | 3.0% | 4.2% | 12.2% | 3.6% |
| Non-Operating Items | |||||
| Interest Income | 20.1M | 18.6M | 27.6M | 14.0M | 11.1M |
| Interest Expense | 42.4M | 57.0M | 23.9M | 16.7M | 27.1M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 48.3M | 66.5M | 151.7M | 541.9M | 325.4M |
| Income Tax | -981.0K | 9.7M | 37.2M | 69.8M | 31.9M |
| Effective Tax Rate % | -2.0% | 14.6% | 24.5% | 12.9% | 9.8% |
| Net Income | 49.3M | 56.8M | 114.5M | 472.2M | 293.5M |
| Net Margin % | 2.5% | 3.3% | 6.7% | 24.2% | 18.1% |
| Key Metrics | |||||
| EBITDA | 205.0M | 159.2M | 208.7M | 444.7M | 227.8M |
| EPS (Basic) | ₹0.64 | ₹0.74 | ₹1.49 | ₹6.16 | ₹3.83 |
| EPS (Diluted) | ₹0.64 | ₹0.74 | ₹1.49 | ₹6.16 | ₹3.83 |
| Basic Shares Outstanding | 76633296 | 76633296 | 76633296 | 76633296 | 76633296 |
| Diluted Shares Outstanding | 76633296 | 76633296 | 76633296 | 76633296 | 76633296 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Ambalal Sarabhai Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 48.9M | 107.5M | 101.3M | 121.0M | 147.4M |
| Short-term Investments | 38.3M | 159.4M | 150.8M | 133.6M | 131.2M |
| Accounts Receivable | 441.4M | 262.6M | 273.4M | 280.6M | 388.1M |
| Inventory | 236.3M | 161.8M | 174.3M | 151.4M | 159.7M |
| Other Current Assets | 48.2M | 64.3M | 30.4M | 32.3M | 29.7M |
| Total Current Assets | 1.2B | 1.2B | 1.1B | 1.2B | 1.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 50.6M | 34.4M | 37.8M | 25.0M | 11.1M |
| Goodwill | 490.2M | 490.3M | 490.6M | 490.7M | 490.7M |
| Intangible Assets | 80.0K | 185.0K | 220.0K | 346.0K | 370.0K |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 981.0K | 663.0K | 2.5M | 15.8M | 121.0K |
| Total Non-Current Assets | 1.5B | 1.3B | 1.3B | 1.1B | 894.6M |
| Total Assets | 2.7B | 2.5B | 2.5B | 2.3B | 2.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 501.5M | 367.0M | 368.4M | 473.0M | 504.0M |
| Short-term Debt | 418.7M | 363.4M | 339.3M | 233.9M | 225.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.7M | 2.0M | 5.0M | 1.7M | 85.4M |
| Total Current Liabilities | 1.2B | 1.0B | 1.0B | 1.1B | 1.3B |
| Non-Current Liabilities | |||||
| Long-term Debt | 90.1M | 97.7M | 112.6M | 33.6M | 53.7M |
| Deferred Tax Liabilities | 0 | 3.2M | 339.0K | 0 | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 96.6M | 107.7M | 119.4M | 51.8M | 76.2M |
| Total Liabilities | 1.3B | 1.1B | 1.1B | 1.1B | 1.4B |
| Equity | |||||
| Common Stock | 766.3M | 766.3M | 766.3M | 766.3M | 766.3M |
| Retained Earnings | -28.3M | -56.8M | -120.2M | -231.4M | -699.2M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.4B | 1.4B | 1.3B | 1.2B | 738.9M |
| Key Metrics | |||||
| Total Debt | 508.9M | 461.1M | 452.0M | 267.5M | 279.4M |
| Working Capital | -19.2M | 162.3M | 80.7M | 147.2M | -79.5M |
Balance Sheet Composition
Ambalal Sarabhai Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 48.3M | 66.5M | 151.7M | 541.9M | 325.4M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -354.9M | -71.6M | 11.4M | -168.2M | -227.0M |
| Operating Cash Flow | -299.7M | -29.3M | 109.4M | 505.0M | 114.4M |
| Investing Activities | |||||
| Capital Expenditures | -25.5M | -24.5M | -192.3M | 35.8M | 89.8M |
| Acquisitions | - | - | - | - | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | 292.0K | 200.0K |
| Investing Cash Flow | 129.6M | -24.5M | -192.3M | 36.1M | 88.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 49.3M | 29.7M | -8.0M | -146.8M | -29.1M |
| Free Cash Flow | -203.3M | 16.1M | -149.4M | -42.4M | -47.6M |
| Net Change in Cash | -120.8M | -24.1M | -91.0M | 394.3M | 174.2M |
Cash Flow Trend
Ambalal Sarabhai Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
23.36
Price to Book
1.72
Price to Sales
1.20
PEG Ratio
0.62
Profitability Ratios
Profit Margin
5.16%
Operating Margin
10.95%
Return on Equity
3.52%
Return on Assets
1.83%
Financial Health
Current Ratio
1.09
Debt to Equity
31.59
Beta
-0.14
Per Share Data
EPS (TTM)
₹1.36
Book Value per Share
₹18.44
Revenue per Share
₹26.42
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| AMBALALSA | 2.4B | 23.36 | 1.72 | 3.52% | 5.16% | 31.59 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





